Reboxetine, sold under the brand name Edronax, is a drug marketed as a treatment for, , and Panic Disorder - amongst others
It is said to work as a norepinephrine reuptake inhibitor (NRI) with special sensitivity for the norepinephrine transporter (NET).
Like, an exact mechanism of action has not yet been found.
Despite widespread efforts to understand the mechanisms of action of antidepressant drugs, the requisite changes in neural function that underlie their therapeutic effects remain unclear. […] However, taken together with previous findings that chronic administration of fluoxetine also results in enhanced activation of LC neurons to a stressor (Page and Abercrombie 1997), our present findings suggest a possible shared mechanistic link between two distinct classes of antidepressant compounds. The exact nature of the mechanism remains unclear but it is likely to rely on the sensitivity of the noradrenergic system to stressors.
Source: Nature Neuropsychopharmacology Vol. 27, pp. 237–247(2002)
Note: A 2010 German study determined that Reboxetine works no better than a .
Ideas for new topics, and suggested additions / corrections for old ones, are always welcome.
If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !
Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.
( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)
You are currently viewing an auto-translated version of Wikenigma
Please be aware that no automatic translation engines are 100% accurate, and so the auto-translated content will very probably feature errors and omissions.
Nevertheless, Wikenigma hopes that the translated content will help to attract a wider global audience.